

University of Groningen

## Apoptosis and colorectal cancer. Studies on pathogenesis and potential therapeutic targets

Koornstra, Jan Jacob

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2006

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Koornstra, J. J. (2006). *Apoptosis and colorectal cancer. Studies on pathogenesis and potential therapeutic targets*. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

*Apoptosis and colorectal cancer*  
*studies on pathogenesis and potential therapeutic targets*

The studies presented in this thesis were supported by the Dutch Cancer Society, grant RUG 1998–1660 (Chapters 4, 5, 6 and 8), grant RUG 2000–2286 (Chapters 2, 3, 4, 6 and 8), a personal fellowship (Chapter 2) and by the Dutch Digestive Disease Foundation, grant WS 2001–31 (Chapters 3, 4, 5, 6 and 8).

The printing of this thesis was supported by the Dutch Digestive Disease Foundation, AstraZeneca, AltanaPharma, Janssen–Cilag, Roche, Schering–Plough and Tramedico.

CIP GEGEVENS KONINKLIJKE BIBLIOTHEEK DEN HAAG

Koornstra, Jan Jacob

Apoptosis and colorectal cancer studies on pathogenesis and potential therapeutic targets  
Proefschrift Groningen.

ISBN: 90–367–2400–7

Copyright © 2006, Jan Jacob Koornstra

All rights reserved. No part of this publication may be reproduced, or transmitted in any form or by any means, without permission of the author.

Schilderij cover: Jentsje Popma, verkaveld landschap, regio Oldambt

Layout: Helga de Graaf, Groningen

Printed by: Print Partners Ipskamp Enschede

RIJKSUNIVERSITEIT GRONINGEN

*Apoptosis and colorectal cancer*  
*studies on pathogenesis and potential therapeutic targets*

Proefschrift

ter verkrijging van het doctoraat in de  
Medische Wetenschappen  
aan de Rijksuniversiteit Groningen  
op gezag van de  
Rector Magnificus, dr. F. Zwarts,  
in het openbaar te verdedigen op  
woensdag 11 januari 2006  
om 16.15 uur

door  
Jan Jacob Koornstra  
geboren op 25 juli 1969  
te Alkmaar

Promotores:

Prof. dr. J.H. Kleibeuker

Prof. dr. E.G.E. de Vries

Prof. dr. H. Hollema

Copromotor:

Dr. S. de Jong

Beoordelingscommissie:

Prof. dr. P.L.M. Jansen

Prof. dr. G.J.A. Offerhaus

Prof. dr. T. Wiggers

Paranimfen:

Drs. Bart W. Schot  
Drs. Sjoerd Hovenga



voor mijn vader  
en mijn moeder





# CONTENTS

Chapter 1	Introduction and outline of the thesis	11
Chapter 2	Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 2003;45:37-53	17
Chapter 3	Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology 2004;44:9-17	47
Chapter 4	Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003;200:327-335	61
Chapter 5	Expression of TRAIL receptors DR4 and DR5 in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 2005;41:1195-1202	77
Chapter 6	Prognostic significance of TRAIL, DR4 and DR5 expression in adjuvant treated stage III colon cancer patients. submitted	91
Chapter 7	Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003;362:230-232	105
Chapter 8	Sulindac inhibits $\beta$ -catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2005;14:1608-1612	115
Chapter 9	Summary, conclusions and future perspectives	129
Chapter 10	Samenvatting, conclusies en toekomstperspectieven	141
	List of publications	153
	Curriculum vitae	157
	Dankwoord	159
	Appendix	165

